Evidence map›Paper›PMID 41315332›Full record

ArticleNature communications2025

Expanding the utility of variant effect predictions with phenotype-specific models.

David Stein, Meltem Ece Kars, Baptiste Milisavljevic, Matthew Mort, Peter D Stenson, Jean-Laurent Casanova, David N Cooper, Bertrand Boisson, Peng Zhang, Avner Schlessinger and 1 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

David SteinDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-5131-8313
Meltem Ece KarsThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-5922-5608
Baptiste MilisavljevicSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0009-0007-0138-4930
Matthew MortDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Peter D StensonDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
Jean-Laurent CasanovaSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
David N CooperDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.ORCID http://orcid.org/0000-0002-8943-8484
Bertrand BoissonSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-5240-3555
Peng ZhangSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-6129-567X
Avner SchlessingerAI Small Molecule Drug Discovery Center, Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. avner.schlessinger@mssm.edu.ORCID http://orcid.org/0000-0003-4007-7814
Yuval ItanDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. yuval.itan@mssm.edu.ORCID http://orcid.org/0000-0003-4966-3238

Funding

Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
Somatic variants as drivers of genetic errors of immunityP01AI186771 · NIAID · WASHINGTON UNIVERSITY · PI Dusan Bogunovic, Megan Anne Cooper · 2025 to 2026
$7.5M
Prenatal medication exposure in autism, birth complications and developmental disabilitiesR01HD107528 · NICHD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MAGDALENA JANECKA, ABRAHAM REICHENBERG · 2022 to 2026
$3.4M
New York Regional Inborn Errors of Immunity Resource Initiative League (NY-ROYAL)R24AI167802 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Dusan Bogunovic, Joshua D. Milner · 2023 to 2026
$3.3M
COVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0M
Big Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0M
Substrate Specificity Determinants in Nutrient Solute Carrier TransportersR01CA277794 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Avner Schlessinger · 2023 to 2026
$1.7M
Structural Studies and Drug Discovery to Interrogate the Function of Neuronal SLC4 TransportersR01NS145483 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Avner Schlessinger, Daniel Wacker · 2025 to 2026
$1.3M
Leona M. and Harry B. Helmsley Charitable Trust (Helmsley Charitable Trust) 2209-05535NCATS NIH HHS UL1 TR004419NCI NIH HHS R01 CA277794NIAID NIH HHS P01 AI186771NIAID NIH HHS R24 AI167802NICHD NIH HHS R01 HD107528NIH HHS S10 OD026880NIH HHS S10 OD030463NINDS NIH HHS R01 NS145483
6 · The paper itself

Abstract

Current methods for variant effect prediction do not differentiate between pathogenic variants resulting in different disease outcomes and are restricted in application due to a focus on variants with a single molecular consequence. We have developed Variant-to-Phenotype (V2P), a multi-task, multi-output machine learning model to predict variant pathogenicity conditioned on top-level Human Phenotype Ontology disease phenotypes (n = 23) for single nucleotide variants and insertions/deletions throughout the human genome. V2P leverages a unique approach for the modeling of variant effect that incorporates resultant disease phenotypes as output and during training to improve the quality of variant disease phenotype and effect predictions, simultaneously. We describe the architecture, training strategy, and biological features contributing to V2P's output, revealing initial characteristics underlying the relationship between disease genotype and phenotype. Moreover, we demonstrate the benefit of incorporating disease phenotypes for variant effect predictions by comparing V2P with several variant effect predictors across various high-quality evaluation datasets from manually curated databases and functional assays. Finally, we examine how V2P's predictions result in the successful identification of pathogenic variants in real and simulated patient sequencing data, outperforming other tested methods in initial comparisons. V2P offers a complete mapping of human genetic variants to disease-phenotypes, offering a uniquely conditioned set of variant effect characterizations.

Indexed as

Computational BiologyGenetic VariationModels, GeneticGenome, HumanGenotypeHumansMachine LearningPhenotypePolymorphism, Single Nucleotide

Identifiers

PMID41315332
PMCPMC12705684

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.